Salvage radiotherapy with or without hormonal therapy for biochemical recurrence after radical prostatectomy: A systematic review and meta-analysis
7 affiliations
- 1Department of Medicine and Surgery, Federico II University, Naples, Italy
- 2Oncology Complex Unit, Santa Maria delle Grazie Hospital, ASL NA2 NORD, 80078 Pozzuoli, Italy
- 3Translational & Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle Upon Tyne, UK
- 4UOC di Oncologia, Azienda Ospedaliera di Rilievo Nazionale Cardarelli di Napoli, Naples, Italy
- 5Department of Radiotherapy and Radiosurgery, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy
- 6Department of Biomedical Sciences, Humanitas University, Pieve Emanuele - Milan, Milan, Italy
- 7Department of Cardiovascular Sciences, Diagnostic Imaging and Time-Dependent Network of Cardiovascular Emergencies, University Hospital “Federico II”, 80128 Naples, Italy
Abstract
Background: Salvage radiotherapy (SRT) is the standard of care for patients with biochemical recurrence (BCR) after radical prostatectomy (RP). Several randomized trials have evaluated the addition of hormonal therapy (HT), including androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs), to SRT; however, differences in patient selection, treatment duration, and endpoints have led to inconsistent results. We performed an updated systematic review and meta-analysis to clarify the clinical benefit of adding HT to SRT in this setting.
Methods: A comprehensive literature search of PubMed/MEDLINE, EMBASE, the Cochrane Library, ClinicalTrials.gov, and ASCO and ESMO meeting abstracts was conducted through April 2025. Randomized phase II-III trials enrolling patients with confirmed BCR after RP and comparing SRT with or without HT were included. Five trials (GETUG-AFU 16, RTOG 9601, RTOG 0534/SPPORT, RADICALS-HD, and SALV-ENZA), comprising 4536 patients, met the eligibility criteria. Hazard ratios (HRs) and 95% confidence intervals (CIs) for metastasis-free survival (MFS), progression-free survival (PFS), biochemical progression-free survival (bPFS), and overall survival (OS) were pooled using fixed- or random-effects models according to heterogeneity. Analyses were stratified by HT duration (short-term vs. long-term), and subgroup analyses were performed based on pathological features.
Results: Short-term HT combined with SRT significantly improved bPFS (HR = 0.57; 95% CI: 0.46–0.71, p < 0.00001), PFS (HR = 0.58; 95% CI: 0.49–0.69; p < 0.00001), and MFS (HR = 0.82; 95% CI: 0.69–0.96; p = 0.02). Long-term HT was also associated with improved MFS (HR = 0.76; 95% CI: 0.61–0.94; p = 0.01). No statistically significant OS benefit was observed with either short-term or long-term HT. Subgroup analyses showed a significant MFS benefit in patients with positive surgical margins (HR = 0.68; 95% CI: 0.47–0.98; p = 0.04), whereas no clear benefit was detected in patients with Gleason score ≥8 or negative margins.
Conclusions: The addition of HT to SRT improves disease control outcomes in patients with BCR after RP, particularly in those with positive surgical margins, although no overall survival benefit was demonstrated. These findings support a tailored approach to treatment intensification in the salvage setting.
Related
- Clinicopathologic Predictors of PSMA-PET Detection, Recurrence Pattern, and Biochemical Outcome Following Salvage Radiotherapy After Radical Prostatectomy
- Pathomic Texture Composites from H&E, and Immunohistochemistry of Prostatectomy Specimens for Exploratory Modeling of Time to Biochemical Recurrence
- Surgical margins and biochemical recurrence after the introduction of robot-assisted radical prostatectomy.
- Interpretable Machine Learning Prognostic Model Integrating Inflammatory-Nutritional Biomarkers for Post-Prostatectomy Biochemical Recurrence: Development, Internal Validation, and Translational Target Exploration.
- Transformer-Based Deep Learning Integrating Multi-Regional MRI and Clinical Features for Predicting Biochemical Recurrence After Radical Prostatectomy: A Multicenter Study.
BibTeX
@article{migliaccio2026salvage,
title = {{Salvage radiotherapy with or without hormonal therapy for biochemical recurrence after radical prostatectomy: A systematic review and meta-analysis}},
author = {Fortuna Migliaccio and Fabiano Flauto and Chiara Barraco and Giuseppe Neola and Sarah Scagliarini and Ciro Franzese and Emanuele Chioccola and Gaetano Facchini and Roberto Bianco and Alberto Servetto and Luigi Formisano},
journal = {Prostate Cancer and Prostatic Diseases},
year = {2026},
month = may,
doi = {10.1038/s41391-026-01120-9},
url = {https://doi.org/10.1038/s41391-026-01120-9},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Salvage radiotherapy with or without hormonal therapy for biochemical recurrence after radical prostatectomy: A systematic review and meta-analysis
AU - Fortuna Migliaccio
AU - Fabiano Flauto
AU - Chiara Barraco
AU - Giuseppe Neola
AU - Sarah Scagliarini
AU - Ciro Franzese
AU - Emanuele Chioccola
AU - Gaetano Facchini
AU - Roberto Bianco
AU - Alberto Servetto
AU - Luigi Formisano
PY - 2026
DA - 2026/05/18
JO - Prostate Cancer and Prostatic Diseases
DO - 10.1038/s41391-026-01120-9
UR - https://doi.org/10.1038/s41391-026-01120-9
AB - Background: Salvage radiotherapy (SRT) is the standard of care for patients with biochemical recurrence (BCR) after radical prostatectomy (RP). Several randomized trials have evaluated the addition of hormonal therapy (HT), including androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs), to SRT; however, differences in patient selection, treatment duration, and endpoints have led to inconsistent results. We performed an updated systematic review and meta-analysis to clarify the clinical benefit of adding HT to SRT in this setting. Methods: A comprehensive literature search of PubMed/MEDLINE, EMBASE, the Cochrane Library, ClinicalTrials.gov, and ASCO and ESMO meeting abstracts was conducted through April 2025. Randomized phase II-III trials enrolling patients with confirmed BCR after RP and comparing SRT with or without HT were included. Five trials (GETUG-AFU 16, RTOG 9601, RTOG 0534/SPPORT, RADICALS-HD, and SALV-ENZA), comprising 4536 patients, met the eligibility criteria. Hazard ratios (HRs) and 95% confidence intervals (CIs) for metastasis-free survival (MFS), progression-free survival (PFS), biochemical progression-free survival (bPFS), and overall survival (OS) were pooled using fixed- or random-effects models according to heterogeneity. Analyses were stratified by HT duration (short-term vs. long-term), and subgroup analyses were performed based on pathological features. Results: Short-term HT combined with SRT significantly improved bPFS (HR = 0.57; 95% CI: 0.46–0.71, p < 0.00001), PFS (HR = 0.58; 95% CI: 0.49–0.69; p < 0.00001), and MFS (HR = 0.82; 95% CI: 0.69–0.96; p = 0.02). Long-term HT was also associated with improved MFS (HR = 0.76; 95% CI: 0.61–0.94; p = 0.01). No statistically significant OS benefit was observed with either short-term or long-term HT. Subgroup analyses showed a significant MFS benefit in patients with positive surgical margins (HR = 0.68; 95% CI: 0.47–0.98; p = 0.04), whereas no clear benefit was detected in patients with Gleason score ≥8 or negative margins. Conclusions: The addition of HT to SRT improves disease control outcomes in patients with BCR after RP, particularly in those with positive surgical margins, although no overall survival benefit was demonstrated. These findings support a tailored approach to treatment intensification in the salvage setting.
SN - 1365-7852
SN - 1476-5608
ER -